-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDB-201 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDB-201 in Metastatic Liver Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDB-201 in Metastatic Liver Cancer Drug Details: Orien X-010 (BDB-201)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cilostazol + Rosuvastatin) in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cilostazol + Rosuvastatin) in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cilostazol + Rosuvastatin)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UI-014 in Endocrine Gland Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UI-014 in Endocrine Gland Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UI-014 in Endocrine Gland Disorders Drug Details: UI-014 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Alpha in Warts
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Alpha in Warts report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Alpha in Warts Drug Details: Interferon alpha (IFN) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alisertib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alisertib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Triple-Negative Breast Cancer (TNBC) Drug Details: Alisertib...
-
Product Insights
NewOveractive Bladder – Drugs In Development, 2024
Empower your strategies with our Overactive Bladder – Drugs In Development, 2024 report and make more profitable business decisions. Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feeling a sudden urge to urinate that's difficult to control, experiencing urge incontinence, and awakening two or more times in the night to urinate. Treatment includes...
-
Product Insights
NewEsophageal Diseases – Drugs In Development, 2024
Empower your strategies with our Esophageal Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Esophageal Diseases, which are characterized by weakened muscles and narrowing of the esophageal opening, often lead to difficulties in digestion and swallowing. The esophagus is the tube-shaped muscle that connects the throat to the stomach. Esophageal diseases occur when the esophagus muscle and opening become weak. The most common problem with the esophagus is GERD (gastroesophageal reflux disease). With GERD, a muscle...
-
Product Insights
NewAllergic Rhinitis – Drugs In Development, 2024
Empower your strategies with our Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy or runny nose, sneezing, swollen...
-
Product Insights
NewNeuropathy – Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...